ASweetLife Team, Author at ASweetLife

First Part of Clinical Trials Completed For InsuLine Diabetes Patch

InsuLine Medical, an Israeli based company whose mission is to develop and market technologies for type 1 and type 2 diabetes, announced that it has completed a first stage clinical trial to examine the effectiveness of its InsuPatch for adults with type 1 diabetes...

XOMA Discovers Two New Classes of Insulin Receptor-Regulating Antibodies

XOMA announced the first presentation of results from its discovery of two new classes of fully human monoclonal antibodies that activate or sensitize the insulin receptor in vivo, each representing a distinct new therapeutic approach to the treatment of patients with diabetes. The data were presented at the American Diabetes Association 71st Scientific Sessions in San Diego...

Victoza Found More Effective Than Byetta and Januvia In Treatment of Type 2 Diabetes

New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not..

Insulin Pump Users Benefit from Symlin

New data from two previously completed clinical studies show that Symlin (pramlintide acetate) helped reduce A1c levels, insulin use and body weight in patients with type 1 diabetes who used insulin pumps. The data was presented by Amylin Pharmaceuticals during...

Adding Byetta to Diabetes Treatment May Reduce Risk Of Heart Failure

Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly...

New Type 2 Diabetes Drug, Bydureon, Shows Positive Effect on A1c and Weight

Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the...

Inhaled Insulin, Afrezza, Does Not Increase Cardiovascular Risk

Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events according to two new studies being presented at the American Diabetes Association's...

Type 2 Diabetes Drug, Linagliptin, Receives Positive Opinion From EMA and CHMP

The European Medicines Agency's (EMA) medicinal committee issued an opinion recommending the approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta in Europe) for the treatment of adults with type 2 diabetes. If adopted by the European Commission, the drug made and distributed by Eli Lilly and Boehringer Ingelheim, will be the only...

Diamyd Terminates US Phase III Study, DiaPrevent

Diamyd Medical has suspended dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd® following consultation with the US Food and Drug Administration (FDA). Termination follows a blinded review of the efficacy data collected to date in the study as well as the previously reported negative outcome...

Actor Chris Noth Joins Novo Nordisk Diabetes Education Campaign

Actor Chris Noth and Novo Nordisk have teamed up in a national education program, Ask.Screen.Know., to highlight the need for early diabetes screening and detection in light of the continuing escalation of diabetes prevalence. As an ambassador for the program, the award-winning actor currently appearing on CBS' show "The Good Wife" and known for his roles as Detective Mike Logan on "Law and Order" and...